

**Regor to Present at 44th Annual JPM Healthcare Conference**

**Jan 08, 2026, 10:00 ET**

Houston, TX, and Shanghai, Jan 05, 2026 – Regor Therapeutics Group, an advanced clinical-stage global biotech company, today announced that Dr. Xiayang Qiu, Founder and Chief Executive Officer, will present the company's corporate strategy and pipeline update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 15, 2026, from 1:45 PM to 2:10 PM PT.

**About Regor Therapeutics Group**

Regor Therapeutics Group is a clinical-stage biotechnology company headquartered in Houston, TX, with operations in Cambridge, San Diego, and Shanghai. With profound biological and mechanistic insights, the company is developing innovative and clinically differentiated medicines to address significant unmet needs in metabolism, oncology, and autoimmunity.

Regor is powered by the highly efficient drug discovery engine rCARD™ (Regor Computer Accelerated Rational Discovery), which enables rapid prototyping and validation of candidate molecules. This rapid approach to developing small molecules against high-profile targets was created by the four co-founders, who collectively bring decades of experience as senior R&D leaders within major global biopharma companies and are the named inventors of four FDA-approved medicines. The power of the rCARD™ platform and approach has been highlighted by out-licensing deals with top companies, including Roche/Genentech for next-gen CDK oncology agents RGT-419B and RGT-587 (now GDC-4198 and GDC-0587), which secured an \$850 million upfront payment in late 2024, following an earlier endocrinology licensing deal with a leading global biopharma.

To learn more about Regor, please visit us at [www.regor.com](http://www.regor.com).

**Contact Information**

ir@regor.com